Orris

Ivabradine in A fib

Reading File
Finding Sources
Searching PubMed

ivabradine AND atrial fibrillation

Searching the Web

ivabradine atrial fibrillation prescribing information contraindication atrial fibrillation

Ivabradine should generally not be used for ventricular rate control in atrial fibrillation (AF).
  • It works mainly by inhibiting the funny (If) current in the sinus node. In AF, atrial activity is not sinus-node driven, so it does not reliably slow the ventricular response.
  • It is not an antiarrhythmic for AF and does not treat or prevent AF.
  • Ivabradine can increase the risk of developing AF. If AF develops in someone taking it, the indication and whether to continue it should be reassessed. The EMA product information states that it is not recommended in AF or other arrhythmias that interfere with sinus-node function.
  • Textbook guidance similarly states it is ineffective for AF rate control and may increase AF risk. Lippincott Illustrated Reviews: Pharmacology, section “Ivabradine.”
For AF with a rapid ventricular rate, usual rate-control options are a beta-blocker, diltiazem/verapamil if appropriate, or digoxin in selected patients. Choice depends on blood pressure, heart failure and ejection fraction, comorbidities, and acuity.
If this concerns a person currently taking ivabradine who now has palpitations, irregular pulse, worsening breathlessness, dizziness, chest pain, or fainting, they should seek prompt medical assessment and ECG confirmation.

How it causes a fib

Reading File
Finding Sources
Searching PubMed

ivabradine AND atrial fibrillation

Searching the Web

ivabradine atrial fibrillation mechanism why risk mechanism

The exact mechanism is not proven. Ivabradine is associated with more newly detected AF in trials, but it is not clear that it directly “causes” every case.
Most plausible explanation:
  1. It blocks HCN (If) channels, not only in the sinus node.
    Ivabradine is designed to slow firing of the sinus node by blocking HCN4-mediated funny current. But HCN channels also exist in atrial tissue, including the pulmonary veins, a common site where AF-triggering electrical impulses arise.
  2. Changing HCN-dependent automaticity may promote atrial ectopic firing or alter atrial electrical stability.
    In a susceptible atrium, such as in heart failure, hypertension, older age, or structural heart disease, this could make AF initiation or persistence more likely. Genetic variants around HCN4 have also been associated with both heart rate and AF, supporting biological plausibility. A randomized-trial meta-analysis describes this proposed pulmonary-vein/HCN-channel mechanism.
  3. Bradycardia may contribute in some people.
    Marked slowing of sinus rhythm can favor atrial ectopic beats and re-entry in predisposed patients, though this is not established as the sole mechanism.
  4. Some of the observed increase may be detection rather than direct causation.
    Patients prescribed ivabradine often already have heart failure or coronary disease, which themselves predispose to AF. Also, the contrast between a slower normal pulse and a faster irregular AF pulse may make AF more symptomatic and more likely to be diagnosed. This is a hypothesis, not settled evidence.
So the accurate summary is: ivabradine blocks HCN/If channels beyond the sinus node, possibly affecting pulmonary-vein and atrial electrophysiology; it is associated with increased AF occurrence, but the direct causal pathway remains uncertain. Product information therefore recommends monitoring and reassessing ivabradine if AF occurs, as stated in the EMA prescribing information.
This is a shared conversation. Sign in to Orris to start your own chat.